Jenny Zilberberg
Research Subjects
Research Interests
Jenny Zilberberg has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Woo Y. Lee
Stevens Institute of Technology - Department of Chemistry and Chemical Biology
4 shared publicationsChristopher Uhl
Department of Research, Imvax, Inc, Philadelphia, Pennsylvania, USA
3 shared publicationsDavid S. Siegel
Center for Discovery and Innovation
3 shared publications- Mark A. Exley
Division of Gastroenterology, Endoscopy, and Hepatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Manchester Collaborative Centre for Inflammation Research, University of Manchester, UK
3 shared publications Qiaoling Sun
Department of Materials Science and Chemical Engineering, Stevens Institute of Technology, Hoboken, NJ, USA
3 shared publicationsWenting Zhang
Department of Chemical Engineering and Materials Science, Stevens Institute of Technology, Hoboken, NJ, 07030, USA
3 shared publications
Latest Publications
- Open Access
- 22 March 2024
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 167 (2) , 369
Correction to: Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy
- 22 March 2024
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 167 (2) , 369
Open AccessCorrection to: Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy
- Open Access
- 29 November 2023
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 165 (3) , 389-398
Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy
Purpose: To date, immunotherapeutic approaches in glioblastoma (GBM) have had limited clinical efficacy as compared to other solid tumors. Here we explore autologous cell treatments that have the potential to circumvent treatment resistance to immunotherapy for GBM. Methods: We performed literature review and assessed clinical outcomes in phase 1 safety trials as well as phase 2 and 3 autologously-derived vaccines for the treatment of newly-diagnosed GBM. In one recent review of over 3,000 neuro-oncology phase 2 and phase 3 clinical trials, most trials were nonblinded (92%), single group (65%), nonrandomized (51%) and almost half were GBM trials. Only 10% involved a biologic and only 2.2% involved a double-blind randomized trial design. Results: With this comparative literature review we conclude that our autologous cell product is uniquely antigen-inclusive and antigen-agnostic with a promising safety profile as well as unexpected clinical efficacy in our published phase 1b trial. We have since designed a rigorous double-blinded add-on placebo-controlled trial involving our implantable biologic drug device. We conclude that IGV-001 provides a novel immunotherapy platform for historically intransigent ndGBM in this ongoing phase 2b trial (NCT04485949).
- 29 November 2023
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 165 (3) , 389-398
Open AccessTargeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy
Purpose: To date, immunotherapeutic approaches in glioblastoma (GBM) have had limited clinical efficacy as compared to other solid tumors. Here we explore autologous cell treatments that have the potential to circumvent treatment resistance to immunotherapy for GBM. Methods: We performed literature review and assessed clinical outcomes in phase 1 safety trials as well as phase 2 and 3 autologously-derived vaccines for the treatment of newly-diagnosed GBM. In one recent review of over 3,000 neuro-oncology phase 2 and phase 3 clinical trials, most trials were nonblinded (92%), single group (65%), nonrandomized (51%) and almost half were GBM trials. Only 10% involved a biologic and only 2.2% involved a double-blind randomized trial design. Results: With this comparative literature review we conclude that our autologous cell product is uniquely antigen-inclusive and antigen-agnostic with a promising safety profile as well as unexpected clinical efficacy in our published phase 1b trial. We have since designed a rigorous double-blinded add-on placebo-controlled trial involving our implantable biologic drug device. We conclude that IGV-001 provides a novel immunotherapy platform for historically intransigent ndGBM in this ongoing phase 2b trial (NCT04485949).
- Open Access
- 7 August 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (8) , e006880
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma
Background: IGV-001 is a personalized, autologous cancer cell-based immunotherapy conceived to deliver a tumor-derived antigenic payload in the context of immunostimulatory signals to patients with glioblastoma (GBM). IGV-001 consists of patient-derived GBM cells treated with an antisense oligodeoxynucleotide against insulin-like growth factor 1 receptor (IGF1R) and placed in proprietary biodiffusion chambers (BDCs). The BDCs are then exposed to 5–6 Gy radiation and implanted at abdominal sites for ~48 hours. IGV-001 has previously been shown to be generally safe with promising clinical activity in newly diagnosed GBM patients. Methods: Mouse (m) or human (h) variants of IGV-001 were prepared using GL261 mouse GBM cells or human GBM cells, respectively. BDCs containing vehicle or mIGV-001 were implanted in the flanks of C57BL/6 albino female mice in preventative and therapeutic experiments, optionally in combination with a programmed cell death 1 (PD-1) blocker. Bioactivity of the general approach was also measured against hepatocellular carcinoma Hepa 1–6 cells. Mice were followed for the growth of subsequently implanted or pre-existing tumors and survival. Draining lymph nodes from mice receiving mIGV-001 were immunophenotyped. mIGV-001 and hIGV-001 were analyzed for extracellular ATP and high mobility group box 1 (HMGB1) as indicators of immunogenic cell death (ICD), along with flow cytometric analysis of viability, surface calreticulin, and reactive oxygen species. Stress and cell death-related pathways were analyzed by immunoblotting. Results: IGV-001 causes oxidative and endoplasmic reticulum stress in GL261 cells, resulting in a cytotoxic response that enables the release of antigenic material and immunostimulatory, ICD-associated molecules including ATP and HMGB1 from BDCs. Immunophenotyping confirmed that IGV-001 increases the percentage of dendritic cells, as well as effector, and effector memory T cells in BDC-draining lymph nodes. Consistent with these observations, preventative IGV-001 limited tumor progression and extended overall survival in mice intracranially challenged with GL261 cells, a benefit that was associated with an increase in tumor-specific T cells with effector features. Similar findings were obtained in the Hepa 1–6 model. Moreover, therapeutically administered IGV-001 combined with PD-1 delayed progression in GBM-bearing mice. Conclusions: These results support treatment with IGV-001 to induce clinically relevant ICD-driven anticancer immune responses in patients with GBM.
- 7 August 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (8) , e006880
Open AccessA biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma
Background: IGV-001 is a personalized, autologous cancer cell-based immunotherapy conceived to deliver a tumor-derived antigenic payload in the context of immunostimulatory signals to patients with glioblastoma (GBM). IGV-001 consists of patient-derived GBM cells treated with an antisense oligodeoxynucleotide against insulin-like growth factor 1 receptor (IGF1R) and placed in proprietary biodiffusion chambers (BDCs). The BDCs are then exposed to 5–6 Gy radiation and implanted at abdominal sites for ~48 hours. IGV-001 has previously been shown to be generally safe with promising clinical activity in newly diagnosed GBM patients. Methods: Mouse (m) or human (h) variants of IGV-001 were prepared using GL261 mouse GBM cells or human GBM cells, respectively. BDCs containing vehicle or mIGV-001 were implanted in the flanks of C57BL/6 albino female mice in preventative and therapeutic experiments, optionally in combination with a programmed cell death 1 (PD-1) blocker. Bioactivity of the general approach was also measured against hepatocellular carcinoma Hepa 1–6 cells. Mice were followed for the growth of subsequently implanted or pre-existing tumors and survival. Draining lymph nodes from mice receiving mIGV-001 were immunophenotyped. mIGV-001 and hIGV-001 were analyzed for extracellular ATP and high mobility group box 1 (HMGB1) as indicators of immunogenic cell death (ICD), along with flow cytometric analysis of viability, surface calreticulin, and reactive oxygen species. Stress and cell death-related pathways were analyzed by immunoblotting. Results: IGV-001 causes oxidative and endoplasmic reticulum stress in GL261 cells, resulting in a cytotoxic response that enables the release of antigenic material and immunostimulatory, ICD-associated molecules including ATP and HMGB1 from BDCs. Immunophenotyping confirmed that IGV-001 increases the percentage of dendritic cells, as well as effector, and effector memory T cells in BDC-draining lymph nodes. Consistent with these observations, preventative IGV-001 limited tumor progression and extended overall survival in mice intracranially challenged with GL261 cells, a benefit that was associated with an increase in tumor-specific T cells with effector features. Similar findings were obtained in the Hepa 1–6 model. Moreover, therapeutically administered IGV-001 combined with PD-1 delayed progression in GBM-bearing mice. Conclusions: These results support treatment with IGV-001 to induce clinically relevant ICD-driven anticancer immune responses in patients with GBM.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2782
Abstract 2782: Machine learning algorithm identifies key serum cytokines associated with evidence of clinical activity in patients treated with personalized immunotherapeutic platform (IGV-00)
Background: IGV-001 is a novel immunotherapy that combines irradiated, patient-derived glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor (IMV-001) in biodiffusion chambers (BDC). We recently reported IGV-001-treated newly diagnosed glioblastoma patients had a median progression free survival of 38.4 months compared with 8.3 months in historical standard-of-care-treated patients (P=0.0008). We have now identified key cytokines and other clinical measures that are predictive of patient outcome via serum profiling and machine learning classification. Methodology: Cytokines in sera were assayed from the day of treatment (0d), 14, 28, 42, and 150d post-treatment. Cytokines quantified included IL-1β, IL-5, IL-6, IL-8, IL-10, IL-13, IL-15, IL-17A, IL-17F, IFNγ, and TNFα. An overall survival cut point of 21.9 months was used to dichotomize ‘good’ vs. ‘poor’ outcomes. MATLAB® Classification Learner was used to train an “optimized tree” predictive model with a sub-population of samples. The trained model was subsequently used to predict survival classification for all patients based on cytokine and clinical data inputs Results: IL-8 showed predictive potential discerning good vs. poor outcomes. Median IL-8 sera concentrations from good (n=10) vs. poor (n=15) responders showed significant differences on 28d (good=7.42 pg/ml, poor=14.73 pg/ml, p=0.027) and 42d (good=4.56 pg/ml, poor=19.87 pg/ml, p=0.0025) compared to 0d (good=8.17 pg/ml, poor=7.42 pg/ml, p=0.8). Training the classification model, a maximum of 4 splits (“Gini’s diversity index” criterion) were possible while achieving 100% correct classification of the training dataset (n=8, good=4, poor=4). Applying the trained model on the full dataset (n=25, good=10, poor=15), resulted in 100% correct classification of patient’s actual clinical outcomes. Analysis of data distributions used by the trained model indicated key cytokine were IL-8, IL-6, and IL-17A. Conclusions: A classification model has been developed to predict long-term “good” vs. short-term “poor” outcomes of IGV-001-treated patients. In particular, we identified IL-8, IL-6 and IL-17A as key immune correlates of patient outcome as early as d14 post-treatment and sustained beyond standard of care treatment. These cytokines are known to correlate with tumor burden, validating the utility of our model. Further inclusion of data from new patients from an upcoming Phase IIb (ClinicalTrials.gov Identifier: NCT04485949) will be utilized to strengthen the model’s predictive capabilities and the potential identification of patient populations most likely to benefit from IGV-001 immunotherapy. Citation Format: Christopher Uhl, Jenny Zilberberg, Charles B. Scott, David W. Andrews, Mark Exley. Machine learning algorithm identifies key serum cytokines associated with evidence of clinical activity in patients treated with personalized immunotherapeutic platform (IGV-00) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2782.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2782
Open AccessAbstract 2782: Machine learning algorithm identifies key serum cytokines associated with evidence of clinical activity in patients treated with personalized immunotherapeutic platform (IGV-00)
Background: IGV-001 is a novel immunotherapy that combines irradiated, patient-derived glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor (IMV-001) in biodiffusion chambers (BDC). We recently reported IGV-001-treated newly diagnosed glioblastoma patients had a median progression free survival of 38.4 months compared with 8.3 months in historical standard-of-care-treated patients (P=0.0008). We have now identified key cytokines and other clinical measures that are predictive of patient outcome via serum profiling and machine learning classification. Methodology: Cytokines in sera were assayed from the day of treatment (0d), 14, 28, 42, and 150d post-treatment. Cytokines quantified included IL-1β, IL-5, IL-6, IL-8, IL-10, IL-13, IL-15, IL-17A, IL-17F, IFNγ, and TNFα. An overall survival cut point of 21.9 months was used to dichotomize ‘good’ vs. ‘poor’ outcomes. MATLAB® Classification Learner was used to train an “optimized tree” predictive model with a sub-population of samples. The trained model was subsequently used to predict survival classification for all patients based on cytokine and clinical data inputs Results: IL-8 showed predictive potential discerning good vs. poor outcomes. Median IL-8 sera concentrations from good (n=10) vs. poor (n=15) responders showed significant differences on 28d (good=7.42 pg/ml, poor=14.73 pg/ml, p=0.027) and 42d (good=4.56 pg/ml, poor=19.87 pg/ml, p=0.0025) compared to 0d (good=8.17 pg/ml, poor=7.42 pg/ml, p=0.8). Training the classification model, a maximum of 4 splits (“Gini’s diversity index” criterion) were possible while achieving 100% correct classification of the training dataset (n=8, good=4, poor=4). Applying the trained model on the full dataset (n=25, good=10, poor=15), resulted in 100% correct classification of patient’s actual clinical outcomes. Analysis of data distributions used by the trained model indicated key cytokine were IL-8, IL-6, and IL-17A. Conclusions: A classification model has been developed to predict long-term “good” vs. short-term “poor” outcomes of IGV-001-treated patients. In particular, we identified IL-8, IL-6 and IL-17A as key immune correlates of patient outcome as early as d14 post-treatment and sustained beyond standard of care treatment. These cytokines are known to correlate with tumor burden, validating the utility of our model. Further inclusion of data from new patients from an upcoming Phase IIb (ClinicalTrials.gov Identifier: NCT04485949) will be utilized to strengthen the model’s predictive capabilities and the potential identification of patient populations most likely to benefit from IGV-001 immunotherapy. Citation Format: Christopher Uhl, Jenny Zilberberg, Charles B. Scott, David W. Andrews, Mark Exley. Machine learning algorithm identifies key serum cytokines associated with evidence of clinical activity in patients treated with personalized immunotherapeutic platform (IGV-00) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2782.
- Open Access
- 1 January 2021
- Published by Elsevier in SSRN Electronic Journal
Natural Killer Cells Activity Against Multiple Myeloma Cells Is Modulated by Osteoblast-Induced IL6 and IL-10 Production
Natural killer (NK) cells are part of the innate arm of the immune system; as such NK cells can be activated rapidly to target virus-infected and tumor cells without prior sensitization. The human NK-92 cell line is among the most widely used NK cells in preclinical research studies and have also been approved for clinical applications. In this study we evaluated how osteoblasts (OSB), which are bone forming cells and a key cellular component of the bone marrow microenvironment, modulate the cytotoxic activity of NK-92 cells against the MM.1S multiple myeloma (MM) cell line. Previous studies have shown that OSB confer drug resistance in MM and other cancers that metastasize to the bone marrow. We report here that in the presence of OSB, NK-92 cells secreted less perforin and granzyme A, resulting in a concomitant decrease in MM.1S cells killing. The physical presence of OSB and NK-92 cells in the cultures also induced IL-6 and IL-10 production; two cytokines which are known to impair the NK cell immunity against multiple myeloma and other cancers. OSB supernatant also conferred cytoprotection to MM.1S, suggesting a dual mechanism by which OSB may modulate both NK and MM cells. As NK cells and their chimeric antigen receptor-modified versions become more widely used in the clinic, our results suggest that understanding the role of OSB as potential immunoregulators of the NK cell mediated cytotoxic response in the bone marrow tumor microenvironment may provide new opportunities for enhancing the activity of this potent immunotherapeutic approach. Funding Information: This study was supported by the National Institutes of Health, grant#: 1R33CA212806-01A1. Declaration of Interests: The authors declare that they have no conflict of interest.
- 1 January 2021
- Published by Elsevier in SSRN Electronic Journal
Open AccessNatural Killer Cells Activity Against Multiple Myeloma Cells Is Modulated by Osteoblast-Induced IL6 and IL-10 Production
Natural killer (NK) cells are part of the innate arm of the immune system; as such NK cells can be activated rapidly to target virus-infected and tumor cells without prior sensitization. The human NK-92 cell line is among the most widely used NK cells in preclinical research studies and have also been approved for clinical applications. In this study we evaluated how osteoblasts (OSB), which are bone forming cells and a key cellular component of the bone marrow microenvironment, modulate the cytotoxic activity of NK-92 cells against the MM.1S multiple myeloma (MM) cell line. Previous studies have shown that OSB confer drug resistance in MM and other cancers that metastasize to the bone marrow. We report here that in the presence of OSB, NK-92 cells secreted less perforin and granzyme A, resulting in a concomitant decrease in MM.1S cells killing. The physical presence of OSB and NK-92 cells in the cultures also induced IL-6 and IL-10 production; two cytokines which are known to impair the NK cell immunity against multiple myeloma and other cancers. OSB supernatant also conferred cytoprotection to MM.1S, suggesting a dual mechanism by which OSB may modulate both NK and MM cells. As NK cells and their chimeric antigen receptor-modified versions become more widely used in the clinic, our results suggest that understanding the role of OSB as potential immunoregulators of the NK cell mediated cytotoxic response in the bone marrow tumor microenvironment may provide new opportunities for enhancing the activity of this potent immunotherapeutic approach. Funding Information: This study was supported by the National Institutes of Health, grant#: 1R33CA212806-01A1. Declaration of Interests: The authors declare that they have no conflict of interest.
- Open Access
- 19 December 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-12
Human ex vivo 3D bone model recapitulates osteocyte response to metastatic prostate cancer
Prostate cancer (PCa) is the second leading cause of cancer deaths among American men. Unfortunately, there is no cure once the tumor is established within the bone niche. Although osteocytes are master regulators of bone homeostasis and remodeling, their role in supporting PCa metastases remains poorly defined. This is largely due to a lack of suitable ex vivo models capable of recapitulating the physiological behavior of primary osteocytes. To address this need, we integrated an engineered bone tissue model formed by 3D-networked primary human osteocytes, with conditionally reprogrammed (CR) primary human PCa cells. CR PCa cells induced a significant increase in the expression of fibroblast growth factor 23 (FGF23) by osteocytes. The expression of the Wnt inhibitors sclerostin and dickkopf-1 (Dkk-1), exhibited contrasting trends, where sclerostin decreased while Dkk-1 increased. Furthermore, alkaline phosphatase (ALP) was induced with a concomitant increase in mineralization, consistent with the predominantly osteoblastic PCa-bone metastasis niche seen in patients. Lastly, we confirmed that traditional 2D culture failed to reproduce these key responses, making the use of our ex vivo engineered human 3D bone tissue an ideal platform for modeling PCa-bone interactions.
- 19 December 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-12
Open AccessHuman ex vivo 3D bone model recapitulates osteocyte response to metastatic prostate cancer
Prostate cancer (PCa) is the second leading cause of cancer deaths among American men. Unfortunately, there is no cure once the tumor is established within the bone niche. Although osteocytes are master regulators of bone homeostasis and remodeling, their role in supporting PCa metastases remains poorly defined. This is largely due to a lack of suitable ex vivo models capable of recapitulating the physiological behavior of primary osteocytes. To address this need, we integrated an engineered bone tissue model formed by 3D-networked primary human osteocytes, with conditionally reprogrammed (CR) primary human PCa cells. CR PCa cells induced a significant increase in the expression of fibroblast growth factor 23 (FGF23) by osteocytes. The expression of the Wnt inhibitors sclerostin and dickkopf-1 (Dkk-1), exhibited contrasting trends, where sclerostin decreased while Dkk-1 increased. Furthermore, alkaline phosphatase (ALP) was induced with a concomitant increase in mineralization, consistent with the predominantly osteoblastic PCa-bone metastasis niche seen in patients. Lastly, we confirmed that traditional 2D culture failed to reproduce these key responses, making the use of our ex vivo engineered human 3D bone tissue an ideal platform for modeling PCa-bone interactions.
- Open Access
- 18 December 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-14
GRP78 modulates cell adhesion markers in prostate Cancer and multiple myeloma cell lines
Glucose regulated protein 78 (GRP78) is a resident chaperone of the endoplasmic reticulum and a master regulator of the unfolded protein response under physiological and pathological cell stress conditions. GRP78 is overexpressed in many cancers, regulating a variety of signaling pathways associated with tumor initiation, proliferation, adhesion and invasion which contributes to metastatic spread. GRP78 can also regulate cell survival and apoptotic pathways to alter responsiveness to anticancer drugs. Tumors that reside in or metastasize to the bone and bone marrow (BM) space can develop pro-survival signals through their direct adhesive interactions with stromal elements of this niche thereby resisting the cytotoxic effects of drug treatment. In this study, we report a direct correlation between GRP78 and the adhesion molecule N-cadherin (N-cad), known to play a critical role in the adhesive interactions of multiple myeloma and metastatic prostate cancer with the bone microenvironment. N-cad expression levels (transcription and protein) were evaluated upon siRNA mediated silencing of GRP78 in the MM.1S multiple myeloma and the PC3 metastatic prostate cancer cell lines. Furthermore, we evaluated the effects of GRP78 knockdown (KD) on epithelial-mesenchymal (EMT) transition markers, morphological changes and adhesion of PC3 cells. GRP78 KD led to concomitant downregulation of N-cad in both tumors types. In PC3 cells, GRP78 KD significantly decreased E-cadherin (E-cad) expression likely associated with the induction in TGF-β1 expression. Furthermore, GRP78 KD also triggered drastic changes in PC3 cells morphology and decreased their adhesion to osteoblasts (OSB) dependent, in part, to the reduced N-cad expression. This work implicates GRP78 as a modulator of cell adhesion markers in MM and PCa. Our results may have clinical implications underscoring GRP78 as a potential therapeutic target to reduce the adhesive nature of metastatic tumors to the bone niche.
- 18 December 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-14
Open AccessGRP78 modulates cell adhesion markers in prostate Cancer and multiple myeloma cell lines
Glucose regulated protein 78 (GRP78) is a resident chaperone of the endoplasmic reticulum and a master regulator of the unfolded protein response under physiological and pathological cell stress conditions. GRP78 is overexpressed in many cancers, regulating a variety of signaling pathways associated with tumor initiation, proliferation, adhesion and invasion which contributes to metastatic spread. GRP78 can also regulate cell survival and apoptotic pathways to alter responsiveness to anticancer drugs. Tumors that reside in or metastasize to the bone and bone marrow (BM) space can develop pro-survival signals through their direct adhesive interactions with stromal elements of this niche thereby resisting the cytotoxic effects of drug treatment. In this study, we report a direct correlation between GRP78 and the adhesion molecule N-cadherin (N-cad), known to play a critical role in the adhesive interactions of multiple myeloma and metastatic prostate cancer with the bone microenvironment. N-cad expression levels (transcription and protein) were evaluated upon siRNA mediated silencing of GRP78 in the MM.1S multiple myeloma and the PC3 metastatic prostate cancer cell lines. Furthermore, we evaluated the effects of GRP78 knockdown (KD) on epithelial-mesenchymal (EMT) transition markers, morphological changes and adhesion of PC3 cells. GRP78 KD led to concomitant downregulation of N-cad in both tumors types. In PC3 cells, GRP78 KD significantly decreased E-cadherin (E-cad) expression likely associated with the induction in TGF-β1 expression. Furthermore, GRP78 KD also triggered drastic changes in PC3 cells morphology and decreased their adhesion to osteoblasts (OSB) dependent, in part, to the reduced N-cad expression. This work implicates GRP78 as a modulator of cell adhesion markers in MM and PCa. Our results may have clinical implications underscoring GRP78 as a potential therapeutic target to reduce the adhesive nature of metastatic tumors to the bone niche.
- 11 December 2018
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 19 (2) , 254-261
Pumpless platform for high-throughput dynamic multicellular culture and chemosensitivity evaluation
We report here a novel pumpless, 96-well plate-based platform for high-throughput dynamic multicellular culture and chemosensitivity evaluation. A gravity-driven flow strategy was developed to generate and sustain the flow rate of culture medium within 10% in the platform's 20 culture chambers. The ability of the platform to generate and sustain the medium flow was demonstrated by computational simulation, flow visualization, and ascertaining the previously known effect of flow-induced shear stress on the stimulated osteogenic differentiation of osteoblasts. The high-throughput utility of the platform was demonstrated by in situ cell staining and high content screening of chemosensitivity assays of multiple myeloma and osteoblast co-cultures. Endpoint characterization and data analyses for all 20 culture chambers required less than 1 hour.
- 11 December 2018
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 19 (2) , 254-261
Pumpless platform for high-throughput dynamic multicellular culture and chemosensitivity evaluation
We report here a novel pumpless, 96-well plate-based platform for high-throughput dynamic multicellular culture and chemosensitivity evaluation. A gravity-driven flow strategy was developed to generate and sustain the flow rate of culture medium within 10% in the platform's 20 culture chambers. The ability of the platform to generate and sustain the medium flow was demonstrated by computational simulation, flow visualization, and ascertaining the previously known effect of flow-induced shear stress on the stimulated osteogenic differentiation of osteoblasts. The high-throughput utility of the platform was demonstrated by in situ cell staining and high content screening of chemosensitivity assays of multiple myeloma and osteoblast co-cultures. Endpoint characterization and data analyses for all 20 culture chambers required less than 1 hour.
- 3 November 2016
- Published by Springer Nature
- Vol. 1513, 171-191
Tissue Engineering Platforms to Replicate the Tumor Microenvironment of Multiple Myeloma
We described here the manufacturing and implementation of two prototype perfusion culture devices designed primarily for the cultivation of difficult-to-preserve primary patient-derived multiple myeloma cells (MMC). The first device consists of an osteoblast (OSB)-derived 3D tissue scaffold constructed in a perfused microfluidic environment. The second platform is a 96-well plate-modified perfusion culture device that can be utilized to reconstruct several tissue and tumor microenvironments utilizing both primary human and murine cells. This culture device was designed and fabricated specifically to: (1) enable the preservation of primary MMC for downstream use in biological studies and chemosensitivity analyses and, (2) provide a high-throughput format that is compatible with plate readers specifically seeing that this system is built on an industry standard 96-well tissue culture plate.
- 3 November 2016
- Published by Springer Nature
- Vol. 1513, 171-191
Tissue Engineering Platforms to Replicate the Tumor Microenvironment of Multiple Myeloma
We described here the manufacturing and implementation of two prototype perfusion culture devices designed primarily for the cultivation of difficult-to-preserve primary patient-derived multiple myeloma cells (MMC). The first device consists of an osteoblast (OSB)-derived 3D tissue scaffold constructed in a perfused microfluidic environment. The second platform is a 96-well plate-modified perfusion culture device that can be utilized to reconstruct several tissue and tumor microenvironments utilizing both primary human and murine cells. This culture device was designed and fabricated specifically to: (1) enable the preservation of primary MMC for downstream use in biological studies and chemosensitivity analyses and, (2) provide a high-throughput format that is compatible with plate readers specifically seeing that this system is built on an industry standard 96-well tissue culture plate.